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Group A rotaviruses (RVA) are the leading cause of morbidity and mortality due to severe 
diarrhoea among children <5 years of age, with nearly 200,000 deaths per year attributable 
to RVA infection globally [1]. RVA belong to the Reoviridae family and have been classified 
as a separate genus Rotavirus. There are 8 wild-type rotavirus groups identified (designated 
groups A to H), 4 of which (groups A, B, C and H) cause disease in humans. Among these 4 
groups, RVA are responsible for more than 90% of all infections in humans [2]. RVA are 
traditionally genotyped based on the sequence diversity of the two outer capsid proteins, 
VP7 (glycosylated, G-type) and VP4 (protease sensitive, P-type), that elicit host-neutralizing 
antibodies and reassort independently from one another in vivo [3]. Six G-genotypes (G1, 
G2, G3, G4, G9 and G12) and three P genotypes (P(4), P(6) and P(8)) reassort in different 
wild-type combinations (G1P(8), G2P(4), G3P(8), G4P(8), G9P(8), and G12P(8)) that 
account for approximately 80%–90% of RVA infections worldwide. Two live-attenuated, 
oral RVA vaccines (RotaTeq®, Merck & Co. NJ, USA and Rotarix®, GSK Biologicals, 
Rixensart, Belgium) have been licensed in >100 countries worldwide since 2006 [4]. In 
2009, the World Health Organization (WHO) issued a global recommendation for use of 
RVA immunization in all children <5 years, to provide protection against severe diarrhoea 
caused by the major RVA strains in circulation [1]. Rotarix® is a monovalent vaccine 
consisting of a human G1P(8) strain and RotaTeq® is a pentavalent vaccine consisting of 5 
human-bovine reassortants expressing the 4 most common human RVA G-types, G1, G2, 
G3, and G4 and the most common human RVA P-type, P(8), on a parental bovine Wistar 
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Calf 3 (WC3) strain backbone. RVA vaccines have significantly reduced RVA associated 
acute gastroenteritis (AGE) and mortality in countries that have implemented RVA 
vaccination [5]. However, Rotarix® and RotaTeq® are live vaccines that can replicate in 
vaccinated children and are shed in feces post vaccination [6,7]. RVA have a segmented 
genome (11 double stranded RNA gene segments) and thus are capable of reassortment. In 
reassortment, two RVA strains infecting the same cell swap genomic segments to produce 
progeny with a mosaic genome containing individual genes from each parent [8]. RotaTeq® 
component strains can reassort with each other to produce reassortant strains causing 
gastroenteritis [8]. Reassortant strains derived from vaccine strains Rotarix® [9] and 
RotaTeq® [10–12] have been associated with AGE in vaccinated [8,13–16] and unvaccinated 
children [17]. Rapid identification of causative agent associated with diarrhea is essential to 
ensure administration of the appropriate patient management and to control potential AGE 
outbreaks. Sensitive and specific high-throughput assays are required to monitor the 
prevalence of vaccine strains in AGE cases and the emergence of new vaccine-derived 
strains following RVA vaccine introduction. Diagnostic techniques to detect RVA in stool 
samples include electron microscopy, virus isolation in cell culture, polyacrylamide gel 
electrophoresis (PAGE) of viral segments, enzyme immunoassays (EIAs), passive particle 
agglutination tests, immunochromatographic tests, RT-PCR and real time or quantitative RT-
PCR (qRT-PCR) [3,18]. Molecular techniques are most sensitive and specific to rapidly 
detect and genotype RVA strains. Several multipathogen detection assays are commercially 
available to simultaneously detect various enteropathogens (viruses including RVA, bacteria 
and parasites) causing gastroenteritis [3]. Molecular techniques used to genotype RVA 
strains include RT-PCR followed by gel based genotyping, qRT-PCR, Sanger sequencing, 
and next generation sequencing [3]. Using qRT-PCR assays to detect and genotype RVA 
offers several advantages over traditional RT-PCR assays including increased sensitivity, 
higher throughput, faster turnaround time, and quantification of viral loads.
One-step, singleplex, qRT-PCR assays have been developed for detection of Rotarix® and 
RotaTeq® vaccine strains in stool samples [19]. Primary qRT-PCR assays were designed for 
vaccine-specific targets in the Rotarix® NSP2 gene, which shows the highest degree of 
genetic dissimilarity between the Rotarix® vaccine strain and other G1P(8) strains and the 
RotaTeq® VP6 gene which detects the presence of the bovine-RVA WC3 backbone in all 
five RotaTeq® component strains. Secondary qRT-PCR assays have been developed for the 
Rotarix® VP4 gene targeting two nucleotide mismatches between Rotarix® vaccine strain 
and wild-type G1P(8) strains. Three RotaTeq® component strains contain a VP3-WC3 gene 
and two component strains contain a VP3-human gene, thus two secondary qRT-PCR assays 
were developed flanking the nucleotides specific to RotaTeq® VP3-WC3 and RotaTeq® 
VP3-human genes. Designed qRT-PCR assays were validated on sequence confirmed stool 
samples containing vaccine strains, wild-type RVA strains of different genotypes and RVA 
negative stools obtained from routine domestic and international RVA surveillance 
conducted by the CDC [19]. For quantification, standard curves were generated using 
dsRNA transcripts derived from RVA gene segments. The qRT-PCR singleplex assays 
exhibited 92–100% sensitivity, 94–100% specificity and a limit of detection of 1–140 copies 
per reaction [19]. These singleplex qRT-PCR assays are used routinely to detect and 
distinguish Rotarix® and RotaTeq® vaccine strains from wild-type RVA strains in 
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surveillance studies. The singleplex qRT-PCR assays developed to detect Rotarix® and 
RotaTeq® vaccine strains [19] are used to detect Rotarix® and RotaTeq® vaccine strains 
using Rotarix NSP2 and RotaTeq VP6 primary assays, respectively, in AGE stool samples 
that tested positive for RVA by EIA or NSP3 gene qRT-PCR (Figure 1) [18]. The positive 
vaccine samples can be confirmed by secondary singleplex qRT-PCRs, the Rotarix VP4 
assay for Rotarix® vaccine and the RotaTeq VP3-WC3 and the RotaTeq VP3-human assays 
for RotaTeq® vaccine.
A one-step, multiplex qRT-PCR assay has been developed to detect and genotype wild-type 
RVA and vaccine strains (Rotarix® and RotaTeq®) in stool samples [20]. A one-step 
multiplex qRT-PCR containing 13 components assays was developed to: 1) detect RVA 
using the NSP3 assay ([18]); 2) detect Rotarix® and RotaTeq® vaccine strains ([19]); 3) 
genotype both wild-type and vaccine RVA strains for VP7 (G1, G2, G3, G4, G9 and G12 
genotypes) and VP4 (P(4), P(6), and P(8) genotypes) genes; and 4) detect an internal process 
control, either Xeno armored RNA (Life Technologies Corp., Grand Island, NY, USA) or 
MS2 (ZeptoMetrix, Buffalo, NY, USA) [20]. The multiplex qRT-PCR assay containing 13 
components is performed in 4 wells; each well contains master mix with primers and probes 
specific for 3–4 target genes with different reporter dyes (FAM, HEX, Texas Red (TR), and 
Cy5). The Well 1 reaction mixture contains primers and probes for RotaTeq-VP6-HEX, 
Xeno or MS2-TR, Rotarix-NSP2-Cy5 and G12-FAM. The Well 2 reaction mixture contains 
primers and probes for G4-FAM, NSP3-TR and G9-HEX. The Well 3 reaction mixture 
contains primers and probes for G1-HEX, P(4)-TR and G3-Cy5. The Well 4 reaction 
mixture contains primers and probes for G2-TR, P(8)-Cy5 and P(6)-FAM. The multiplex 
qRT-PCR assay was validated on large number of sequence confirmed stool samples 
(containing wild-type or vaccine/vaccine derived RVA strains), vaccine strains, RVA 
negative samples and lab-cultured strains of different genotypes. The multiplex qRT-PCR 
assay was validated by generating standard curves using dsRNA transcripts that were 
generated artificially from RVA gene segments. All the qRT-PCR assays were performed in 
96-well ABI Fast plates using the GeneAmp EZ rTth RNA PCR kit (Applied Biosystems 
Inc.-ABI, Foster City, USA) which is now discontinued by ABI. In a multiplex format, 
NSP3, Rotarix® and RotaTeq®, VP7 and VP4 qRT-PCRs, displayed 81–93% efficiency with 
a limit of detection of 10–4000 copies per reaction [20]. All the qRT-PCR assays have been 
tested using the EMD Millipore-One step RT-PCR Master Mix kit (EMD Chemicals Inc., 
Billerica, MA, USA) and the limit of detection is comparable to that of the GeneAmp EZ 
rTth kit (unpublished data).
The vaccine detection singleplex assays have been incorporated into the one step multiplex 
qRT-PCR assay to detect and genotype wild-type RVA and vaccine strains [20]. The 
multiplex qRT-PCR assay can be used on AGE samples directly or on selected RVA positive 
samples tested by EIA or NSP3 gene qRT-PCR. This multiplex qRT-PCR (4 wells, 13 
components) assay will detect RVA by NSP3 gene qRT-PCR, will detect vaccine strains 
(Rotarix® and RotaTeq®) by Rotarix NSP2 and RotaTeq VP6 qRT-PCRs and will genotype 
the RVA strains for six VP7 (G1, G2, G3, G4, G9, and G12) and three VP4 (P(4), P(6), and 
P(8)) genotypes along with a Xeno or MS2 internal process control. The samples testing 
positive for vaccine strains by multiplex qRT-PCR assay are confirmed for vaccine strains by 
using secondary assays, Rotarix-VP4 for Rotarix® positive samples and RotaTeq VP3-WC3 
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and RotaTeq VP3-human assays for RotaTeq® positive samples (Figure 1). We recommend 
that a representative subset of wild-type RVA samples and all the samples found to contain 
vaccine strains should be sequenced by Sanger sequencing or Next Gen sequencing to 
confirm the genotypes obtained by the multiplex qRT-PCR assay.
The limitations of singleplex and multiplex qRT-PCR assays evaluated in this study are that 
the samples with G and P combinations not covered in this assay won’t be genotyped. Also, 
these assays won’t detect reassortants between wild-type RVA rotavirus and vaccine strains 
involving gene segments other than VP4, VP7 and NSP2 genes for Rotarix® vaccine strain 
and VP4, VP7, VP6 and VP3 genes for RotaTeq® vaccine strains.
These qRT-PCR assays (both in singleplex and multiplex formats) facilitate high-throughput 
detection and genotype characterization of wild-type RVA, vaccine strains and RotaTeq® 
vaccine derived G1P(8) reassortant strains in stools samples from AGE patients. These 
assays will also determine the frequency of vaccine or RotaTeq® vaccine derived G1P(8) 
strains in stool samples during routine RVA surveillance.
Acknowledgments
We would like to thank Ms. Leanne Ward for her critical review of the manuscript and the figure.
Funding Source
Funding for this study was provided by the Centers for Disease Control and Prevention
References
1. Tate JE, Burton AH, Boschi-Pinto C, Parashar UD, World Health Organization-Coordinated Global 
Rotavirus Surveillance Network. Global, Regional, and National Estimates of Rotavirus Mortality in 
Children <5 Years of Age, 2000–2013. Clin Infect Dis. 2016; 62:96–105.
2. Estes, MK., Kapikian, A. Rotaviruses. In: Knipe, DM., editor. Fields Virology. Kluwer/Lippincott, 
Williams and Wilkins; Philadelphia, PA: 2007. p. 1917-1974.
3. Esona MD, Gautam R. Rotavirus. Clin Lab Med. 2015; 35:363–391. [PubMed: 26004648] 
4. Parashar UD, Johnson H, Steele AD, Tate JE. Health Impact of Rotavirus Vaccination in Developing 
Countries: Progress and Way Forward. Clin Infect Dis. 2016; 62(Suppl 2):S91–95. [PubMed: 
27059361] 
5. Patel MM, Steele D, Gentsch JR, Wecker J, Glass RI, et al. Real-world impact of rotavirus 
vaccination. Pediatr Infect Dis J. 2011; 30:S1–5. [PubMed: 21183833] 
6. Anderson EJ. Rotavirus vaccines: viral shedding and risk of transmission. Lancet Infect Dis. 2008; 
8:642–649. [PubMed: 18922486] 
7. Yen C, Jakoba K, Esonab MD, Peckhama X, Rauscha J, Hullb JJ, et al. Detection of fecal shedding 
of rotavirus vaccine in infants following their first dose of pentavalent rotavirus vaccine. Vaccine. 
2011; 29:4151–4155. [PubMed: 21477676] 
8. Bowen MD, Payne DC. Rotavirus vaccine-derived shedding and viral reassortants. Expert Rev 
Vaccines. 2012; 11:1311–1314. [PubMed: 23249230] 
9. Rose TL, Marques da Silva MF, Goméz MM, Resque HR, Ichihara MY, et al. Evidence of vaccine-
related reassortment of rotavirus, Brazil, 2008–2010. Emerg Infect Dis. 2013; 19:1843–1846. 
[PubMed: 24188273] 
10. Patel NC, Hertel PM, Estes MK, de la Morena M, Petru AM, et al. Vaccine-acquired rotavirus in 
infants with severe combined immunodeficiency. N Engl J Med. 2010; 362:314–319. [PubMed: 
20107217] 
Gautam and Bowen Page 4













11. Werther RL, Crawford NW, Boniface K, Kirkwood CD, Smart JM. Rotavirus vaccine induced 
diarrhea in a child with severe combined immune deficiency. J Allergy Clin Immunol. 2009; 
124:600.
12. Roy S, Rungsrisuriyachai K, Esona MD, Boom JA, Sahni LC, et al. G2P[4]-RotaTeq Reassortant 
Rotavirus in Vaccinated Child, United States. Emerg Infect Dis. 2015; 21:2103–2104. [PubMed: 
26488454] 
13. Boom JA, Sahni LC, Payne DC, Gautam R, Lyde F, et al. Symptomatic infection and detection of 
vaccine and vaccine-reassortant rotavirus strains in 5 children: a case series. J Infect Dis. 2012; 
206:1275–1279. [PubMed: 22872730] 
14. Hemming M, Vesikari T. Vaccine-derived human-bovine double reassortant rotavirus in infants 
with acute gastroenteritis. Pediatr Infect Dis J. 2012; 31:992–994. [PubMed: 22581224] 
15. Donato CM, Ch’ng LS, Boniface KF, Crawford NW, Buttery JP, et al. Identification of strains of 
RotaTeq rotavirus vaccine in infants with gastroenteritis following routine vaccination. J Infect 
Dis. 2012; 206:377–83. [PubMed: 22615314] 
16. Bucardo F, Rippinger CM, Svensson L, Patton JT. Vaccine-derived NSP2 segment in rotaviruses 
from vaccinated children with gastroenteritis in Nicaragua. Infect Genet Evol. 2012; 12:1282–
1294. [PubMed: 22487061] 
17. Payne DC, Edwards KM, Bowen MD, Keckley E, Peters J, et al. Sibling transmission of vaccine-
derived rotavirus (RotaTeq) associated with rotavirus gastroenteritis. Pediatrics. 2010; 125:e438–
e441. [PubMed: 20100758] 
18. Mijatovic-Rustempasic S, Tam KI, Kerin TK, Lewis JM, Gautam R, et al. Sensitive and specific 
quantitative detection of rotavirus A by one-step real-time reverse transcription-PCR assay without 
antecedent double-stranded-RNA denaturation. J Clin Microbiol. 2013; 51:3047–54. [PubMed: 
23850952] 
19. Gautam R, Esona MD, Mijatovic-Rustempasic S, Ian Tam K, Gentsch JR, et al. Real-time RT-PCR 
assays to differentiate wild-type group A rotavirus strains from Rotarix(®) and RotaTeq(®) 
vaccine strains in stool samples. Hum Vaccin Immunother. 2014; 10:767–777. [PubMed: 
24342877] 
Gautam and Bowen Page 5














Flow chart showing qRT-PCR assays developed for RVA detection (NSP3 assay), vaccine 
strain detection in singleplex format (Rotarix® NSP2-primary assay, Rotarix® VP4-
secondary assay; RotaTeq® VP6- primary assay, RotaTeq® VP3-WC3 and VP3-human-
secondary assays) and multiplex qRT-PCR (13 components) assay to detect and genotype 
RVA wild-type and vaccine strains in AGE stool samples.
Gautam and Bowen Page 6
J Vaccines Vaccin. Author manuscript; available in PMC 2017 April 12.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
